

ABSTRACT

Alpha-santalol, a major component of sandalwood oil inhibits growth of cultured prostate cancer cells in vitro by causing apoptosis. The present study was undertaken to determine the *in vivo* efficacy of α -santalol using TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice as a model. Administration of α -santalol (100 mg/kg) significantly decreased the incidence of prostate tumors, average wet weights of urogenital organs and prostate weight compared to control mice. Furthermore, the dorsolateral sections of prostate from α -santaloltreated mice exhibited decreased cell proliferation (Ki-67 staining) in association with induction of apoptosis (TUNEL-positive cells). In agreement with immunohistochemical analysis, Western blotting analysis of prostate/tumor samples from α santalol-treated group revealed a decrease in survivin, XIAP, PCNA, cyclin D and CDC2 levels compared to control samples. c-RAF, a protooncogene was also downregulated in alpha-santalol treated group compared to the control group. In conclusion, the present study indicates that α -santalol administration inhibits the development of prostate cancer in TRAMP mice by decreasing cell proliferation, and inducing apoptosis and warrants future studies for its clinical development. This study was supported by Wilkes University's Provost Research grant and mentoring grant.

Chemopreventive Potential of Alpha-Santalol in a Mouse Model of Prostate Cancer

John Oberlin¹, Kaitlyn Blankenhorn¹, Sarah Hughes¹, Erica Mabry¹, Aaron Knopp¹ Isaiah Pinkerton² Linda Gutierrez², Adam VanWert¹ and Ajay Bommareddy¹

> ¹Department of Pharmaceutical Sciences ²Department of Biology

RESULTS Animal study protocol **Animal Sacrifice** at Effect of alpha-santalol on cell proliferation 26-28 weeks of age Intraperitoneal administration 5-6 week old Collection of prostate, of alpha-santalol or control **TRAMP** mice tumor and vital organs for for 20 weeks, 3 times per week (9 per group) data analysis The mouse genitourinary tract Macroscopic examination 3 mice per cage Injections given under general anesthesia Effect of alpha-santalol on tumor incidence Effect of alpha-santalol on body weight 55.60% (5/9) Effect of alpha-santalol on apoptosis --- Control → Alpha-santalol 32.5-<u>ි</u>කු 30.0-20-11.10% (1/9) Alpha-santalol Control group Time (weeks) Effect of alpha-santalol on prostate/tumor morphology Effect of alpha-santalol on GU weight Expression of cell cycle and proliferation markers Alpha-santalol Control 1.50-Cyclin D 1.25-CDC2 2.75 0.75 cRaf Survivin 0.50-0.25-XIAP 0.00-**PCNA** Alpha-santalol Control group group

SUMMARY

- >Administration of control/vehicle and alpha-santalol in TRAMP mice did not result in any abnormal weight gain/loss through out the study.
- >Alpha-santalol treatment resulted in a significant decrease in tumor incidence and genitourinary tract (GU) and prostate weights compared to control-treated mice.
- >Mice treated with alpha-santalol exhibited decreased cell proliferation (Ki-67 staining) in association with induction of apoptosis (TUNEL-positive cells).
- >Western blotting analysis of prostate/tumor samples from α-santalol-treated group revealed a decrease in survivin, XIAP, PCNA, cyclin D and CDC2 levels compared to control-treated samples.